Larsson, Kjell
Kankaanranta, Hannu http://orcid.org/0000-0001-5258-0906
Janson, Christer
Lehtimäki, Lauri http://orcid.org/0000-0003-1586-4998
Ställberg, Björn
Løkke, Anders http://orcid.org/0000-0002-6905-4141
Høines, Kristian
Roslind, Klaus
Ulrik, Charlotte Suppli
Funding for this research was provided by:
AstraZeneca (N/A, N/A, N/A, N/A, N/A, N/A, N/A, N/A)
Article History
Received: 14 February 2020
Accepted: 21 April 2020
First Online: 5 June 2020
Competing interests
: K.L. has, during the last 5 years, on one or more occasion served in an advisory board and/or served as speaker and/or participated in education arranged by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Orion, Novartis, and Teva. H.K. has received institutional grants, personal fees and non-financial support from AstraZeneca, personal fees from Chiesi Pharma AB, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Novartis, personal fees from Mundipharma, personal fees and non-financial support from Orion Pharma, personal fees from SanofiGenzyme, personal fees from GlaxoSmithKline, outside the submitted work. C.J. has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Meda and Teva and has served on advisory boards arranged by AstraZeneca, Boehringer Ingelheim, Novartis, Meda, Teva and GlaxoSmithKline. L.L. has received honoraria for educational activities, lectures or advisory boards from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Orion, Sanofi and Teva. B.S. has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, Novartis, Meda, and Teva and has served on advisory boards arranged by AstraZeneca, Boehringer Ingelheim, Novartis, Meda, Teva and GlaxoSmithKline. A.L. has received fees for lectures and for educational activities from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, GlaxoSmithKline, Mundipharma and Novartis, and has participated in advisory boards arranged by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Pfizer and Novartis. Furthermore, he has received grants for research from Pfizer, Boehringer Ingelheim and Novartis, as well as research-related travel accommodation from AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, GlaxoSmithKline, Mundipharma, Orion and Novartis. A.L. has previously been/is currently a principal investigator in pharmaceutical company-sponsored research studies for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Novartis. K.H. has received honoraria for educational activities, lectures and advisory boards from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Orion Pharma, and Teva. K.R. has, during the last 5 years, on one or more occasion served in an advisory board and/or served as speaker and/or participated in education arranged by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva. C.S.U. has received honoraria for educational activities, lectures and advisory boards from AstraZeneca, GlaxoSmithKline, Sanofi, Mundipharma, TEVA, Boehringer Ingelheim, Novartis, Orion Pharma, Actelion, ALK-Abello, and Sandoz.